metricas
covid
Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) Substance abuse and gender differences in first episode psychosis: Impact on hos...
Información de la revista
Vol. 11. Núm. 1.
Páginas 27-35 (enero - marzo 2018)
Visitas
2638
Vol. 11. Núm. 1.
Páginas 27-35 (enero - marzo 2018)
Brief report
Acceso a texto completo
Substance abuse and gender differences in first episode psychosis: Impact on hospital readmissions
Consumo de sustancias y diferencias de género en personas afectas de un primer episodio psicótico: impacto en los porcentajes de reingreso
Visitas
2638
Josep M. Crosasa, Jesus Coboa,b,
Autor para correspondencia
jcobo@tauli.cat

Corresponding author.
, Maribel Ahuira, Carla Hernándeza,c, Rebeca Garcíaa, Esther Pousad,e, Joan-Carles Olivaf, José-Antonio Monreala,b, Diego J. Palaoa,b
a Salut Mental, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain
b Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
c Servei Salut Mental, Escaldes-Engordany, Andorra
d Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain
e Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain
f Unitat d’Estadística, Fundació Parc Taulí, Sabadell, Barcelona, Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
Mostrar másMostrar menos
Tablas (3)
Table 1. Characteristics of the sample (n=141).
Table 2. Characteristics of readmissions.
Table 3. Kaplan–Meier survival analysis.
Mostrar másMostrar menos
Abstract
Introduction

There have been controversial results in the study of gender differences in first episode psychosis (FEP). Substance abuse is the main existing comorbidity in FEP, and has been associated with worse prognosis and greater symptom severity.

Objectives

To explore gender differences in FEP in relation to drug abuse, and their relationship with hospital readmissions.

Methodology

Descriptive and prospective study (18 months).

Results

We included 141 patients (31.2% women), aged 26.1 years on average, mostly diagnosed with schizophreniform disorder (32.6%). A percentage of 58.9 had problematic use of drugs. Gender significant differences were found in age of onset, age at entry to the programme, marital status and cohabitation, and percentage differences were revealed in current drug abuse and frequency of consumption. Gender, duration of untreated psychosis, psychiatric history, age of onset and previous drug use were not predictors of re-entry. Hospital readmission rate was 24.8%, with no gender differences. The most common reasons for admission were abandonment of treatment (66.7%) and drug abuse (44.4%). Drug abuse was higher in the men than in the women as a reason for re-admission.

Conclusions

There are gender differences in FEP. Men have an earlier onset of symptoms and have worse functional outcomes. Drug abuse in men is higher and represents a major cause of hospital readmission. Therapeutic interventions to prevent the effects of drug abuse are necessary from the early stages of the illness.

Keywords:
Psychosis
First psychotic episode
Drugs of abuse
Gender
Hospital admission
Resumen
Introducción

El estudio de diferencias de género en primeros episodios psicóticos (PEPs) ha aportado resultados controvertidos en los últimos años. El consumo de sustancias es la principal comorbilidad en PEPs, y se ha relacionado con un peor pronóstico y con una mayor gravedad sintomática.

Objetivos

Explorar las diferencias de género en PEPs en relación con el consumo de sustancias, así como su relación con los reingresos hospitalarios.

Metodología

Analítico y prospectivo (18 meses).

Resultados

Incluimos 141 pacientes (31,2% mujeres), con una edad media de 26,1 años, mayoritariamente diagnosticadas de trastorno esquizofreniforme (32,6%). Un 58,9% presentan algún consumo problemático de sustancias. Encontramos diferencias significativas de género en la edad de inicio, de ingreso en el programa, el estado civil y la convivencia, y diferencias en el consumo de sustancias actual y la frecuencia de consumo. El género, la duración de la psicosis no tratada, los antecedentes psiquiátricos, la edad de inicio o el consumo de sustancias previo no fueron factores predictores de reingreso. El porcentaje de reingreso hospitalario fue del 24,8%, sin diferencias de género. Entre los motivos más frecuentes de ingreso se encuentran el abandono del tratamiento (66,7%) y el consumo de sustancias (44,4%), siendo mayor en los hombres el consumo de sustancias como motivo de reingreso.

Conclusiones

Existen diferencias de género en PEPs. Los hombres inician más tempranamente los síntomas, con peores resultados funcionales. El consumo de sustancias en hombres es mayor y representa un importante motivo de reingreso hospitalario. Intervenciones terapéuticas dirigidas a prevenir su efecto son necesarias desde las primeras fases.

Palabras clave:
Psicosis
Primeros episodios psicóticos
Drogas de abuso
Género
Ingreso hospitalario
Texto completo
Introduction

The impact of mental illnesses on the European population is constantly increasing. The overall burden of neuropsychiatric disorders accounted for 18.4% of the total years of life adjusted for disability.1 In people affected by a first psychotic episode (FEPs), the first years of treatment are crucial in subsequent clinical and functional evolution. However, up to 52.0% of patients present in a poor condition at the time of starting therapeutic programmes, even specific ones. Furthermore, as high as 37% of them continue with a low functional status at completion of the programmes and even 18% of those who started with good functionality, lose this.2

During the last decade, the study of gender differences in FEPs has become a topic of interest. In fact, members of the different samples of FEPs tend to be males, with non-affective psychoses, poorer levels of premorbid adjustment, poorer education and a greater tendency to present self-reported accounts of learning difficulties, medical-legal problems, traumatic experiences and substance abuse.2 However, as Arranz et al.,3 point out, in many studies the gender variable has been used as a covariate or as a predictor in statistical analysis, and there are few studies which have considered gender as the result or central hypothesis of the study.3–10 Even so, some of the results between gender and FEPs regarding clinical and prognostic variables remain contradictory or inconsistent.11

One of the most conclusive findings regarding gender differences in psychosis and FEPs has been the age of onset, this being earlier for men,3,11,12 although other studies have not been able to corroborate this.5,9 The difference between gender and premorbid functioning has also been replicated, this being generally better among women.5,11,12 Regarding symptoms, studies that have found gender differences4,5,9,12 suggest that men have more severe negative symptoms, while women show more affective symptoms.11 Regarding the duration of untreated psychosis (DUP), although studies continue to show that men have a tendency to a longer DUP compared to women3,4,6 a review could not confirm this.13

A series of studies have analyzed gender differences in prognosis, course and evolution after FEPs, with contradictory results. It has been described that men have a poorer prognosis.5 Male gender (and the presence of negative symptoms) also predicts poorer functionality in FEPs at 2 years of follow-up.14 The observed heterogeneity of gender differences in psychotic disorder may be attributable to methodological differences between epidemiological studies (sample selection, sample size or other factors).5

Substance use is common among patients diagnosed with recent-onset psychoses and schizophrenia, and is shown to be the main comorbidity in FEPs.11 It has also been related to a worse prognosis and more serious symptoms.11

On the other hand, in the general population, several studies have reported a higher prevalence of substance abuse in men, with higher levels of comorbidity for substance use disorders.11 Men in the general population have greater comorbidity with the use of cannabis, cocaine and hallucinogens, while women may record greater abuse of anxiolytics. Nonetheless, other population studies show greater consumption in women.15 This data must be taken into account when interpreting results from clinical samples.

It is known that up to 30–60% of patients affected by FEPs relapse during the first 2 years of evolution14 and that during the first 5 years of evolution there is a higher risk of relapses and re-admissions, worsening the prognosis. There are different factors that influence these relapses and hospital readmissions. However, these have not yet been sufficiently analyzed in our environment, especially their relationship with gender.

Aims

  • 1.

    To explore gender differences in people diagnosed with FEPs related to substance use.

  • 2.

    To establish the relationship between substance use by gender and hospital readmissions.

Methodology

Design: analytical and prospective

Sample: patients consecutively included in the FEP Corporació Sanitària Parc Taulí programme (Sabadell) between January 2010 and October 2014. The Corporació belongs to the public network and serves a reference population of 430,000 inhabitants, mostly urban and employed in the economy, industry and services sector. This is the only hospital that treats serious mental illness in the area.

Inclusion criteria: age between 18 and 35 years, affected by any first episode with psychotic symptoms according to the DSM-IV-TR (American Psychiatric Association, 2002): schizophreniform disorder, schizophrenia (and subtypes), schizoaffective disorder (and subtypes), unspecified psychotic disorder, brief psychotic disorder, episodes of bipolar disorder (and subtypes) or major depressive disorder with psychotic symptoms. Exclusion criteria: psychosis due to medical illness as a result of the consumption of substances and patients with mental retardation. Description of the programme: the FEPs programme at the Corporació Sanitària Parc Taulí emerges as a need for specific attention to be paid to incipient psychosis with the objective, on the one hand, of early detection in all the areas of Primary and Specialized Healthcare in the area and, on the other hand, with the clinical objective of obtaining the best therapeutic results once the process has begun. Specific care is provided in both psychiatric and psychotherapeutic areas, with group and individual sessions, rehabilitation strategies and re-entry to work or education, where appropriate. Likewise, our programme has a specific section on psychoeducation and family follow-up, as well as coordinating the different levels of care and resources. As regards development and inclusion and exclusion criteria, in general the programme follows the recommendations laid down in the Development Guide of Specific Care for Incipient Psychosis produced by the Catalonian regional government.16

Instruments: a questionnaire to compile sociodemographic data and personal and family psychiatric records. The age of onset of symptoms, the DUP and the Brief Psychosis Rating Scale17 were included here. The toxicological data (personal and family) included problematic consumption contributed by the patient, the family, the clinical history, or in analytical data. The evolutionary data mainly included the date of the first hospital admission (if any) after entering the programme.

In our population, in the absence of a more consensus-based definition and taking into account both the most prevalent use of cannabis and the high frequency of associated consumption, we considered problematic consumption of any substance that produces problems for the consumer or their environment, and within these problems we would include: problems of physical or mental health, social problems and even risky behaviour that could endanger the life or health of the consumer.18

Follow-up: 18 months from entry to the programme.

Statistical analysis: descriptive and comparative according to parametric and non-parametric tests, as indicated (Student t or Mann–Whitney U for continuous variables and Chi-square or Fisher's exact test for categorical ones). Due to the exploratory nature and performance of multiple comparisons, we agreed on a significance level of less than .01.

Finally, we ran Kaplan–Meier survival analysis. We considered 25 years as the cut-off age (median of our sample) for the survival analysis in relation to the age of onset (Fig. 1). For the analysis of the DUP, we considered the division, of 12 months as a cut-off point,19 as proposed by Thomas and Nandhra in 2009.

Figure 1.

Kaplan–Meier survival analysis by age of onset.

(0.1MB).
Results

These are summarized in Table 1: a total of 141 patients took part, with an average age of 26.1 years at the beginning of the programme. A total of 31.2% were women, 65.2% were single and 61.7% resided with their family of origin. The majority were detected in the Emergency Department and were included after a first hospital admission (91.5%). The most frequent diagnosis was schizophreniform disorder (32.6%). Up to 58.9% of patients presented some problematic use of associated substances, especially cannabis (50.4%) and alcohol (33.3%). During the 18 months of follow-up, the abandonment rate was 12%. We found gender differences in the age of onset of symptoms, the age of admission into the programme, marital status and current cohabitation (Table 1). We also found a greater tendency towards significance in terms of current substance consumption and the frequency of consumption in women. Gender, DUP, personal or family psychiatric history, age at onset or substance use prior to the start of the programme did not show up as predictors of readmission (Table 2). Nor did the diagnoses influence hospital admissions after entering the programme. A rate of 24.8% of hospital readmissions was recorded during the 18 months of follow-up, without gender differences (Table 2). Among the most frequent reasons for admission were the abandonment of treatment (66.7%) and the consumption of substances (44.4%). There was a tendency to significance in terms of substance consumption as the reason for readmission, this being higher in men.

Table 1.

Characteristics of the sample (n=141).

  Total  Women  Men  p 
  No.=141  n=44 (31.2%)  n=97 (68.8%)   
Age of onset of symptoms (years), mean (SD), range  25.4 (5.0), 17–35  27.4 (5.1)  24.4 (4.7)  .002 
DUP. mean (SD)  17.2 (25.6)  15.2 (26.1)  18.2 (25.2)  .557 
Age at entry to programme (years), mean (SD), range  26.1 (5.1), 18–35  28.2 (5.1)  25.1 (4.9)  .001 
Provenance, n (%).371 
Hospital admission  129 (91.5)  41 (93.2)  88 (90.7)   
Emergency (no admission)  4 (2.8)  0 (0.0)  4 (4.1)   
Mental health centre  8 (5.7)  3 (6.8)  5 (5.2)   
Marital status, n (%)a.008 
Single  92 (65.2)  21 (50.0)  71 (78.0)   
Married/stable partner  25 (17.7)  12 (28.6)  13 (14.3)   
Separated/divorced  15 (10.6)  8 (19.0)  7 (7.0)   
Widower  1 (0.7)  1 (2.4)  0 (0.0)   
Has children, n (%)  25 (17.7)  13 (31.0)  12 (13.5)  .030 
Cohabiting, n (%)a<.001 
Alone  9 (6.4)  3 (7.1)  6 (6.6)   
Original family  87 (61.7)  20 (47.6)  67 (73.6)   
Treatment flat  1 (0.7)  0 (0.0)  1 (1.1)   
Own family  24 (17.0)  17 (40.5)  7 (7.7)   
Friends  12 (8.5)  2 (4.8)  10 (11.0)   
Level of education, n (%)a.606 
No education  21 (14.9)  6 (15.8)  15 (18.8)   
Primary  50 (35.5)  14 (36.8)  36 (45.0)   
Secondary  34 (24.1)  12 (31.6)  22 (27.5)   
University  13 (9.2)  6 (15.8)  7 (8.8)   
Personal PSI/PSQ background, n (%)a,b  34 (24.1)  16 (38.1)  18 (20.5)  .053 
Anxiety disorder  6 (4.3)  3 (18.8)  3 (16.7)   
Monopolar affective disorder  12 (8.5)  6 (37.5)  6 (33.3)   
Bipolar affective disorder  1 (0.7)  0 (0.0)  1 (5.6)   
Autism Spectrum Disorder  1 (0.7)  0 (0.0)  1 (5.6)   
ADHD  3 (2.1)  0 (0.0)  3 (16.7)   
Personality disorder  4 (2.8)  4 (25.0)  0 (0.0)   
Adaptive disorder  3 (2.1)  2 (12.5)  1 (5.6)   
TCA  1 (0.7)  1 (6.3)  0 (0.0)   
Unspecified mental disorder  3 (2.1)  2 (12.5)  3 (16.7)   
Diagnosis at discharge, n (%)a  141 (100.0)  44 (100.0)  97 (100.0)  .108 
Schizophreniform disorder  46 (32.6)  7 (15.9)  39 (40.2)   
Schizophrenia (and subtypes)  7 (5.0)  2 (4.5)  5 (2.5)   
Squizoaffective disorder (and subtypes)  3 (2.1)  1 (2.3)  2 (2.1)   
Bipolar disorder (and subtypes)  26 (18.4)  11 (25.0)  15 (15.5)   
Mayor depressive disorder with psychotic symptoms  6 (4.3)  3 (6.8)  3 (3.1)   
Unspecified psychotic disorder+brief psychotic disorder  53 (37.6)  20 (45.5)  33 (34.0)   
Current TOX, n (%)a,c  83 (58.9)  20 (48.8)  63 (70.0)  .031 
Alcohol  47 (33.3)  10 (22.7)  37 (38.1)  .084 
Cannabis  71 (50.4)  17 (38.6)  54 (55.7)  .071 
Cocaine  13 (9.2)  1 (2.3)  12 (12.4)  .064 
Designer drugsd  5 (3.5)  1 (2.3)  4 (4.1)  1.000 
Frequency of use, n (%)e.035 
Occasional  32 (22.7)  11 (25.0)  21 (21.6)   
Frequent  31 (22.0)  6 (13.6)  25 (25.8)   
Disorder  18 (12.8)  2 (4.5).  16 (16.5)   
PSI/PSQ, family background n (%)a,f  52 (36.9)  17 (41.5)  35 (38.5)  .848 
Psychotic disorder  22 (15.6)  6 (35.3)  16 (50.0)   
Anxiety disorder  2 (1.4)  2 (11.1)  0 (0.0)   
Monopolar affective disorder  17 (12.1)  8 (47.1)  9 (28.1)   
Affective bipolar disorders  3 (2.1)  0 (0.0)  3 (9.4)   
Autism Spectrum Disorder  1 (0.7)  0 (0.0)  1 (3.1)   
Personality Disorder  2 (1.4)  0 (0.0)  2 (6.3)   
Adaptive disorder  2 (1.4)  1 (5.9)  1 (3.1)   
TOX family history, n (%)a,b,c,g  20 (14.2)  3 (7.3)  17 (19.5)  .110 
BPRS (start), mean (SD)  29.0 (8.4)  27.0 (8.6)  29.7 (8.3)  .395 
Pharmacological treatment at entry to programme, n (%)
Antipsychotics  141 (100)  44 (100)  97 (100)  – 
Mood stabilizers  23 (16.3)  8 (18.2)  15 (15.5)  .686 
Antidepressants  18 (12.8)  6 (13.6)  12 (12.5)  .835 
Benzodiazepines  66 (46.8)  18 (40.9)  48 (49.5)  .344 

BPRS (start): Brief Psychosis Rating Scale at start of first admission. SD: standard deviation; DUP: duration in weeks of untreated psychosis, before the first admission; ED: eating disorder; ADHD: attention deficit and hyperactivity disorder; ASD: autism spectrum disorders.

a

Some values do not correspond to the total n's due to the missing values.

b

Psychological and psychiatric history of the patient prior to admission at first psychotic episode.

c

Excessive/problematic use of substances (some patients consume more than one or two problematic substances).

d

Include methamphetamine (Speed), MMDA (Ecstasy), GHB (liquid ecstasy) and ketamine.

e

The consumption of toxic substances on entry to the programme includes patients with occasional consumption (intermittent use of the substance(s), without a fixed pattern and with long intervals of abstinence), frequent (habitual) and of substance consumption disorder, which includes patients with substance abuse or dependence according to the DSM-IV-TR criteria (American Psychiatric Association, 2002).

f

Psychological and psychiatric history in first-degree relatives.

g

History of abusive/problematic use of substances in first-degree relatives. The p-value has been calculated using the corresponding tests: Student's t test or Mann–Whitney U test, Chi-square test or Fisher's exact test (bilateral). Significant if p<.01.

Table 2.

Characteristics of readmissions.

  Total  Women  Men  p 
  No.=141  n=44 (31.2%)  n=97 (68.8%)   
Readmissions 18 months, n (%)a  35 (24.8)  8 (18.2)  27 (27.8)  .219 
Reasons for readmission, n (%)b
A: substance use  16 (44.4)  1 (12.5)  15 (53.6)  .045 
B: abandoned treatment  24 (66.7)  4 (50.0)  20 (71.4)  .257 
A+14 (38.9)  1 (12.5)  13 (46.4)  .083 
C: Suicide attempt  5 (14.7)  1 (12.5)  4 (15.4)  1.000 
D: Other reasons  6 (17.6)  3 (37.5)  3 (11.5)  .126 
Time (years) to first admission post-inclusion, mean (SD), range  .57 (.47), .04–1.52  .37 (.34), .04–.87  .63 (.50), .06–1.52  .236; U=77.00 
a

Readmission 18 months after entering programme.

b

Percentage refers to readmitted patients. Some patients may have several reasons for readmission. The p value was calculated with the corresponding tests: Student t or Mann–Whitney U, Chi-squared or Fisher's exact test (bilateral). Significant if p<.01.

In the Kaplan–Meier survival analysis, as shown in Table 3, gender and other factors analyzed did not result in a differential impact for the time of patients’ admission during the follow-up period. Fig. 2 shows the survival analysis by gender, where we found no differences. Fig. 3 shows the survival analysis by DUP while Fig. 1 shows the survival analysis in relation to the age of onset.

Table 3.

Kaplan–Meier survival analysis.

  Time to admission (CI 95%)  p, Log Rank (Mantel–Cox) 
Gender
Men  15.1 (13.9–16.2)  .261 
Women  15.5 (13.9–17.1)   
DUP
Under 12 weeks  15.4 (14.2–16.6)  .384 
Equal to or over 12  14.8 (13.2–16.5)   
Personal history of PSI/PSQ
No  15.5 (14.5–16.5)  .453 
Yes  14.2 (12.0–16.4)   
Family history of PSI/PSQ
No  15.4 (14.3–16.6)  .936 
Yes  14.8 (13.2–16.5)   
Current substance consumption
No  15.2 (13.6–16.7)  .601 
Yes  15.1 (13.9–16.3)   
Age of onset
Under 25 years  14.2 (12.7–15.8)  .072 
Equal to or over 25  16.1 (15.0–17.3)   

DUP: duration of untreated psychosis; CI 95%: confidence interval of 95%; PSI/PSQ: psychological/psychiatric history.

Figure 2.

Kaplan–Meier survival analysis by gender.

(0.1MB).
Figure 3.

Kaplan–Meier survival analysis by duration of untreated psychosis (DUP).

(0.1MB).

Considering 25 years as the cut-off age (median of our sample), the analysis on survival in relation to the age of onset (Fig. 1), although not significant either, confirms more rapid admission in patients who began substance abuse at a younger age (below or equal to 25 years).

Discussion

To our knowledge, this is the first analysis in our environment that explores gender differences as the reason for hospital readmission in patients with FEPs. Our results confirm some previous ones in terms of gender differences in psychosis, such as a younger age at onset in men3,4,9,12,13,20,21 and greater difficulties with independent cohabitation also in men.5,9 As in other studies, we did not find gender differences in DUP,6–9,13 on the Brief Psychosis Rating Scale at entry to the programme,21 or in the clinical diagnosis when starting the programme,12 among other variables in the study.

However, our results show that maintaining consumption of substances was one of the main causes of re-admission, as was also shown by the review and meta-analysis by Alvarez-Jimenez et al.22 with a possible gender effect.

Substance use was very prevalent among people affected by FEPs, with different results depending on the samples.23–25 For example, the study by Wade et al.23 with 103 FEPs recorded at 3 mental health centres and followed up for 15 months, showed how substance abuse was independently related to an increased risk of readmission, relapses in positive symptoms, and a shorter time of relapse for positive symptoms. In the same direction, the study by Arranz et al.3 and others5,9,26 show how men consumed more substances in general and to a significant extent. In our sample, no significant differences were found, although men consumed more substances in percentage terms. Among the possible explanations for these differences were the characteristics of the sample itself, the assessment instruments, or effects arising from changes in the general population as regards the consumption of substances.

In this sense, currently, according to the Government Delegation for the National Plan on Drugs,27 the main legal substance consumed among Spanish women is alcohol, followed by tobacco and cannabis. Nonetheless, there has been a worrying increase in cocaine use and tranquilizers and hypnosedatives. Similarly, although epidemiological samples still detect a higher prevalence of alcohol and other drug abuse among men, as compared to women, an increase in prevalence has also been observed among women.28

There is some evidence of greater severity in cocaine addiction in women.29 In fact, in samples of young Americans, the proportion of young women with cocaine dependence is higher than among young men (p<.01).28 However, this North American data is not replicated in our adolescent and youth population.27 Regarding cannabis, in Spain this continues to be the most widely consumed illegal substance, affecting 13.6% of men as compared to 5.5% of women. Fortunately, however, there has been a decrease in consumption for both sexes as compared with the 2009 figures.27 The problem is that its use is widely and socially accepted in general and, unfortunately, in the case of women, consumption has grown since the first statistics.30

The high prevalence of substance use found in our sample of patients is in agreement with the overall percentages found in previous studies3,5,6 ranging from 68–80% in men and 30–51% in women.

Regarding the percentages of readmissions in our sample, these were similar to rates observed in other follow-up studies at 18 months and are in agreement with other previously reported results, ranging from 24–36% of relapses at 18 months.22

Although some studies5 have reported that men are more likely to have one or more hospitalizations during follow-up at 18 months, we did not find gender differences in the percentage of readmissions. Therefore, it seems that gender is not a predictor of future readmissions.

In our study, gender was not shown as a predictor of readmission, as in previous studies.22,31 Nor did DUP or other initial variables, or even intake of substances before entry to the programme show themselves to be predictors. This indicates the importance of other factors but also the need to maintain substance abstinence in these early stages of the illness. As regards the influence of substance use on re-admission percentages, our results showed trends towards a gender differential effect that should be explored more thoroughly in the future. Likewise, the moderating impact of gender on other relapse factors should also be explored, such as lack of adherence to treatment15 or lack of insight.12 In fact, advances in the treatment of our patients must take into account a much more personalized and targeted approach, with special attention to therapeutic aspects32 but also to the specific ones related to gender.

Limitations and strong points of the study

The main limitations of the study are the absence of systematic analytical determinations of substances and the geographically-bound characteristics of the sample. As main strengths, the adequacy of the sample, since our programme is the only service provider in the area, as well as covering specific analysis of hospital readmissions, not only of relapses, following psychometric criteria.

Conclusions

There are gender differences in FEPs. Men manifest symptoms earlier and may at that point present poorer functional results. The rate of substance use is higher in men and it is also a key reason for hospital readmission.

Interventions aimed at alleviating (and preventing) the effects of substance use in people affected by FEPs are necessary from the early stages of treatment.

Ethical responsibilitiesProtection of human and animal subjects

The authors declare that no experiments have been conducted on humans or animals for this research.

Confidentiality of data

The authors declare that they have followed the protocols laid down by their work centre on the publication of patient data.

Right to privacy and informed consent

The authors declare that no patient information appears in this article.

Conflict of interest

The authors declare no conflict of interest.

References
[1]
E. Lara, N. Garin, A.J. Ferrari, S. Tyrovolas, B. Olaya, L. Sánchez-Riera, et al.
La carga de enfermedad en España 2010: trastornos neurológicos, mentales y relacionados.
Rev Psiquiatr Salud Ment (Barc), 8 (2015), pp. 207-217
[2]
S.M. Cotton, M. Lambert, B.G. Schimmelmann, K. Filia, V. Rayner, L. Hides, et al.
Predictors of functional status at service entry and discharge among young people with first episode psychosis.
Soc Psychiatry Psychiatr Epidemiol, 52 (2017), pp. 575-585
[3]
B. Arranz, I. Corripio, G. Safont, N. Ramirez, R.M. Dueñas, V. Perez, et al.
Susbtance use in first-episode psychosis: does gender matter?.
J Schizophr Res, 2 (2015), pp. 1015
[4]
A. Koster, M. Lajer, A. Lindhart, B. Rosenbaum.
Gender differences in first episode psychosis.
Soc Psychiatr Epidemiol, 43 (2008), pp. 940-946
[5]
S.M. Cotton, M. Lambert, B.G. Schimmelmann, D.L. Foley, K.I. Morley.
Gender differences in premorbid, entry, treatment, and outcome characteristics in a treatment epidemiological sample of 661 patients with first episode psychosis.
Schizophr Res, 114 (2009), pp. 17-24
[6]
W. Chang, J. Tang, C. Hui, C. Chui, M.M. Lam, G.H. Wong, et al.
Gender differences in patients presenting with first-episode psychosis in Hong Kong: a three-year follow up study.
Aust N Z J Psychiatry, 45 (2011), pp. 199-205
[7]
J.S. Choi, M.W. Chon, D.H. Kang, M.H. Jung, J.S. Kwon.
Gender difference in the prodromal symptoms of first-episode schizophrenia.
J Korean Med Sci, 24 (2009), pp. 1083-1088
[8]
M. Mattsson, L. Flyckt, G. Edman, H. Nyman, J. Cullberg, Y. Forsell.
Gender differences in the prediction of 5-year outcome in first episode psychosis.
Int J Methods Psychiatr Res, 16 (2007), pp. 208-218
[9]
A. Torup, L. Petersen, P. Jeppesen, J. Ohlenschlaeger, T. Christensen, G. Krarup, et al.
Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study.
J Nerv Ment Dis, 195 (2007), pp. 396-405
[10]
A. Torup, N. Albert, M. Bertelsen, L. Petersen, P. Jeppesen, P. Le Quack, et al.
Gender differences in first-episode psychosis at 5-year follow-up--Two different courses of disease? Results from the OPUS study at 5-year follow-up.
Eur Psychiatry, 29 (2014), pp. 44-51
[11]
S. Ochoa, J. Usall, J. Cobo, X. Labad, J. Kulkarni.
Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review.
Schizophr Res Treat, 2012 (2012), pp. 916198
[12]
C. Catton, H. Xie, R.E. Drake, G. McHugo.
Gender differences in psychotic disorders with concurrent substance use.
J Dual Diagn, 10 (2014), pp. 177-186
[13]
M.T. Cascio, M. Cella, A. Preti, A. Meneghelli, A. Cocchi.
Gender and duration of untreated psychosis: a systematic review and meta-analysis.
Early Interv Psychiatry, 6 (2012), pp. 115-127
[14]
D. Bergé, A. Mané, P. Salgado, R. Cortizo, C. Garnier, L. Gomez, et al.
Predictors of relapse and functioning in first-episode psychosis: a two-year follow-up study.
Psychiatr Serv, 67 (2016), pp. 227-233
[15]
K. Donoghue, I. Medley, J. Brewin, C. Glazebrook, P. Mason, R. Cantwell, et al.
The association between substance misuse and first-episode psychosis in a defined UK geographical area during the 1990s.
Soc Psychiatry Psychiatr Epidemiol, 46 (2011), pp. 137-142
[16]
X.P. Viaña.
Guia de desenvolupament del programa d’atenció específica a les persones amb trastorns psicòtics incipients del Pla director de salut mental i addiccions, 2011.
[17]
J.E. Overall, D.R. Gorham.
The brief psychiatric rating scale.
Psychol Rep, 10 (1962), pp. 799-812
[18]
D. Klempova, A. Sánchez, J. Vicente, G. Barrio, A. Domingo, J.M. Suelves, et al.
Informe sobre Consumo Problemático de Cannabis en estudiantes. España 2009. Consumo problemático de cannabis en estudiantes españoles de 14-18 años: validación de escalas. Informes, Estudios e Investigación en Drogodependencias, Ministerio de Sanidad y Política Social. Estudio colaborativo entre la Delegación del Gobierno para el Plan Nacional sobre Drogas y el Observatorio Europeo de las Drogas y las Toxicomanías.
Ministerio de Sanidad y Política Social, (2009),
[19]
S.P. Thomas, H.S. Nandhra.
Early intervention in psychosis: a retrospective analysis of clinical and social factors influencing duration of untreated psychosis.
Prim Care Companion J Clin Psychiatry, 11 (2009), pp. 212-214
[20]
M. Bertani, A. Lasalvia, C. Bonetto, S. Tosato, D. Cristofalo, S. Bissoli, et al.
The influence of gender on clinical and social characteristics of patients at psychosis onset: a report from the Psychosis Incident Cohort Outcome Study (PICOS).
Psychol Med, 42 (2012), pp. 769-780
[21]
A. Cocchi, A. Lora, A. Meneghelli, E. La Greca, A. Pisano, M.T. Cascio, et al.
Sex differences in first-episode psychosis and in people at ultra-high risk.
Psychiatry Res, 215 (2014), pp. 314-322
[22]
M. Alvarez-Jimenez, A. Priede, S.E. Hetrick, S. Bendall, E. Killackey, A.G. Parker, et al.
Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies.
Schizophr Res, 139 (2012), pp. 116-128
[23]
D. Wade, S. Harrigan, J. Edwards, P.M. Burgess, G. Whelan, P.D. McGorry.
Substance misuse in first-episode psychosis: 15-month prospective follow-up study.
Br J Psychiatry, 189 (2006), pp. 229-234
[24]
T.R. Barnes, S.H. Mutsatsa, S.B. Hutton, H.C. Watt, E.M. Joyce.
Comorbid substance use and age at onset of schizophrenia.
Br J Psychiatry, 188 (2006), pp. 237-242
[25]
M.T. Compton, M.E. Kelley, C.E. Ramsay, M. Pringle, S.M. Goulding, M.L. Esterberg, et al.
Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients.
Am J Psychiatry, 166 (2009), pp. 1251-1257
[26]
R. Mazzoncini, K. Donoghue, J. Hart, C. Morgan, G.A. Doody, P. Dazzan, et al.
Illicit substance use and its correlates in first episode psychosis.
Acta Psychiatr Scand, 121 (2010), pp. 351-358
[27]
Delegación del Gobierno para el Plan Nacional sobre Drogas.
Informe 2016. Alcohol, tabaco y drogas ilegales en España. Observatorio Español de la Droga y las Toxicomanías. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, Secretaría de Estado de Servicios Sociales e Igualdad, Delegación del Gobierno para el Plan Nacional sobre Drogas.
[28]
J.H. Cotto, E. Davis, G.J. Dowling, J.C. Elcano, A.B. Staton, S.R. Weiss.
Gender effects on drug use, abuse, and dependence: a special analysis of results from the National Survey on Drug Use and Health.
Gend Med, 7 (2012), pp. 402-413
[29]
S.J. Robbins, R.N. Ehrman, A.R. Childress, C.P. O’Brien.
Comparing levels of cocaine cue reactivity in male and female outpatients.
Drug Alcohol Depend, 53 (1999), pp. 223-230
[30]
N. Romo Avilés.
Mujeres. Mirando desde el género los usos de drogas.
Tratado SET de trastornos adictivos. Tomo II, pp. 522-526
[31]
O. Caseiro, R. Pérez-Iglesias, I. Mata, O. Martínez-Garcia, J.M. Pelayo-Terán, R. Tabares-Seisdedos, et al.
Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study.
J Psychiatr Res, 46 (2012), pp. 1099-1105
[32]
E. Vieta.
La medicina personalizada aplicada a la salud mental: la psiquiatría de precisión.
Rev Psiquiatr Salud Ment (Barc), 8 (2015), pp. 117-118

Please cite this article as: Crosas JM, Cobo J, Ahuir M, Hernández C, García R, Pousa E, et al. Consumo de sustancias y diferencias de género en personas afectas de un primer episodio psicótico: impacto en los porcentajes de reingreso. Rev Psiquiatr Salud Ment (Barc). 2018;11:27–35.

Copyright © 2017. SEP y SEPB
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos